Happe, Svenja

[["dc.bibliographiccitation.firstpage","1401"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1406"],["dc.bibliographiccitation.volume","254"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kundmueller, Lotte"],["dc.contributor.author","Reichelt, Doris"],["dc.contributor.author","Husstedt, Ingo-W."],["dc.contributor.author","Evers, Stefan"],["dc.date.accessioned","2018-11-07T10:58:13Z"],["dc.date.available","2018-11-07T10:58:13Z"],["dc.date.issued","2007"],["dc.description.abstract","Background The lifetime prevalence of restless legs syndrome (RLS) is about 10 % in the general population. The association of RLS with HIV infection is unknown. We aimed to investigate the prevalence of RLS in HIV positive patients and to define predictors. Methods A standardized questionnaire was presented to 228 HIV infected patients of the HIV outpatient clinic at the Department of Neurology,University of Munster, Germany. 129 patients (57% recall; 15% female, 44 +/- 9 years; mean CD4(+) cell count 333 +/- 274/mu l, 82% under highly active antiretroviral treatment) were included in the statistical analysis. 100 age- and sex-matched controls (20 % female, 42 +/- 13 years) were recruited from waiting relatives of surgical patients. Beside demographic and disease-specific data, the questionnaire included the diagnostic questions for RLS and the RLS severity scale by the International RLS Study Group. Diagnosis of RLS was confirmed by experienced neurologists. Results 33.3% of the HIV infected patients and 7% of the controls (p < 0.001) fulfilled the diagnostic criteria for RLS. The mean RLS severity score was higher in HIV infected patients (19.5 +/- 7.2) than in controls (7.3 +/- 1.5; p < 0.001) and correlated inversely with the CD4(+) cell count (r = -0.381; p = 0.024) and the BMI (r = -0.548; p < 0.001) but not with other disease-specific factors. Conclusions HIV infected patients show a significantly higher prevalence rate for RLS than the general population. The HIV infection itself with its immunological changes and involvement of the central nervous system may predispose for a risk of RLS in HIV infected patients."],["dc.identifier.doi","10.1007/s00415-007-0563-2"],["dc.identifier.isi","000250442500015"],["dc.identifier.pmid","17934881"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50430"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Comorbidity of restless legs syndrome and HIV infection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","184"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","185"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Steinig, Jana"],["dc.contributor.author","Kloesch, Gerhard"],["dc.contributor.author","Sauter, Cornelia"],["dc.contributor.author","Zeitlhofer, Josef"],["dc.contributor.author","Happe, Svenja"],["dc.date.accessioned","2018-11-07T11:04:50Z"],["dc.date.available","2018-11-07T11:04:50Z"],["dc.date.issued","2007"],["dc.identifier.doi","10.1016/j.sleep.2006.08.008"],["dc.identifier.isi","000245090900015"],["dc.identifier.pmid","17275406"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51932"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1389-9457"],["dc.title","Actigraphy in irregular sleep-wake rhythm"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Dodel, R."],["dc.date.accessioned","2018-11-07T11:07:35Z"],["dc.date.available","2018-11-07T11:07:35Z"],["dc.date.issued","2007"],["dc.format.extent","A281"],["dc.identifier.isi","000246224900820"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52601"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","21st Annual Meeting of the Association-Professional-Sleep-Societies"],["dc.relation.eventlocation","Minneapolis, MN"],["dc.relation.issn","0161-8105"],["dc.title","Direct and indirect costs of restless legs syndrome (RLS)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hogl, Birgit"],["dc.contributor.author","Gschliesser, V."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiu, G."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T08:48:03Z"],["dc.date.available","2018-11-07T08:48:03Z"],["dc.date.issued","2005"],["dc.format.extent","A272"],["dc.identifier.isi","000228906101316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21113"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","19th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Denver, CO"],["dc.relation.issn","0161-8105"],["dc.title","Augmentation during long-term treatment with L-DOPA in restless legs syndrome: Results of a multicentric study in Europe"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","696"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","703"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Grote, Ludger"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Mathis, Johannes"],["dc.contributor.author","Saletu-Zyhlarz, Gerda M."],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T11:03:11Z"],["dc.date.available","2018-11-07T11:03:11Z"],["dc.date.issued","2007"],["dc.description.abstract","We report the first large-scale double-blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Methods: Patients with idiopathic RLS were treated with fixed daily doses of 2 or 3 mg CAB or 200 or 300 mg levodopa for 30 weeks. Efficacy was assessed by changes in the IRLS (International RLS Severity Scale) and by time to disconfirmation of treatment due to loss of efficacy or augmentation. 361 of 418 screened patients (age 58 +/- 12 years, 71% females) were randomly assigned and treated (CAB: n = 178; levodopa: n = 183) in 51 centers of four European countries. Baseline IRLS total score was 25.7 +/- 6.8. The baseline-adjusted mean change from baseline to week 6 in IRLS sum score was d = -16.1 in the CAB group and d = -9.5 in the levodopa group (d = -6.6, P < 0.0001). More patients in the levodopa group (24.0%) than in the CAB group (11.9%, P = 0.0029, log-rank test) discontinued because of loss of efficacy (14.2% vs. 7.9%, P = 0.0290) or augmentation (9.8% vs. 4.0%, P = 0.0412). Adverse events (AEs) occurred in 83.1% of the CAB group and in 77.6% of the levodopa group. In both groups, most frequent AEs were gastrointestinal symptoms (CAB: 55.6%, levodopa: 30.6%, P < 0.0001). This first large-scale active controlled study in RLS showed superior efficacy of cabergoline versus levodopa after a 30-week long-term therapy. Tolerability was found more favorable with levodopa than with cabergoline. (c) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21401"],["dc.identifier.isi","000246213100015"],["dc.identifier.pmid","17274039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51559"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Cabergoline compared to levodopa in the treatment of patients with severe Restless Legs Syndrome: Results from a multi-center, randomized, active controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1037"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1043"],["dc.bibliographiccitation.volume","254"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Baier, Paul Christian"],["dc.contributor.author","Helmschmied, Kathrin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Tatsch, Klaus"],["dc.contributor.author","Paulus, Walter J."],["dc.date.accessioned","2018-11-07T11:00:13Z"],["dc.date.available","2018-11-07T11:00:13Z"],["dc.date.issued","2007"],["dc.description.abstract","Many patients with Parkinson's disease (PD) report daytime sleepiness. Its etiology, however, is still not fully understood. The aim of this study was to examine if the amount of nigrostriatal dopaminergic degeneration is associated with subjective daytime sleepiness in patients with PD. We investigated 21 patients with PD clinically and by means of [I-123] FP-CIT-SPECT (DaTSCAN(R)). Each patient filled in the Epworth sleepiness scale (ESS), the Parkinson's Disease Sleep Scale (PDSS), and the self-rating depression scale according to Zung (SDS) to assess sleepiness, sleep quality, and depressive symptoms. The mean specific dopamine transporter binding in the 21 PD patients (60.8 +/- 10.4 years, nine females, median Hoehn and Yahr stage 2.0) was decreased. Nine patients were in Hoehn and Yahr stage 1 (58.7 +/- 6.6 years, four females; ESS score 7.4 +/- 4.5; PDSS score 105.1 +/- 30.9), the other 12 patients were in Hoehn and Yahr stage 2 (62.4 +/- 12.6 years, five females; ESS score 6.7 +/- 4.7, PDSS score 97.1 +/- 25.6). Age, gender, ESS, and PDSS scores were not significantly different in both groups. However, ESS scores showed an inverse correlation with mean DAT binding in the striatum (r = -0.627, p = 0.03), the caudate nucleus (r = -0.708, p = 0.01), and the putamen (r = -0.599, p = 0.04) in patients with Hoehn and Yahr stage 2. There was no correlation of the ESS score with age, disease duration, UPDRS motor score, PDSS score, or depression score. Subjective daytime sleepiness seems to be associated with dopaminergic nigrostriatal degeneration in early PD."],["dc.identifier.doi","10.1007/s00415-006-0483-6"],["dc.identifier.isi","000249205900009"],["dc.identifier.pmid","17351722"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50880"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1255"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cephalalgia"],["dc.bibliographiccitation.lastpage","1260"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Rhode, A. M."],["dc.contributor.author","Hoesing, V. G."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Biehl, K."],["dc.contributor.author","Young, P."],["dc.contributor.author","Evers, Stefan"],["dc.date.accessioned","2018-11-07T10:55:39Z"],["dc.date.available","2018-11-07T10:55:39Z"],["dc.date.issued","2007"],["dc.description.abstract","In order to evaluate a possible association between migraine and restless legs syndrome (RLS), we performed a case-control study on the comorbidity of RLS and migraine. Patients with migraine (n = 411) and 411 sex- and age-matched control subjects were included. Migraine was diagnosed according to International Headache Society criteria, RLS according to the criteria of the International Restless Legs Syndrome Study Group. Furthermore, all patients had to fill out a self-assessment test performance on depression [Beck's Depression Inventory (BDI)]. RLS frequency was significantly higher in migraine patients than in control subjects (17.3% vs. 5.6%, P < 0.001; odds ratio 3.5, confidence interval 2.2, 5.8). In our sample, there was no significant association between migraine and depression as defined by the BDI score (9.6% in migraine vs. 4.0% in control subjects, P = 0.190). Depression was, however, not significantly more frequent in migraine patients with RLS (13.6%) than in migraine patients without RLS (8.7%). In addition, migraine patients with RLS had a significantly higher BDI score. RLS features did not differ significantly between migraine patients with RLS and control subjects with RLS. There is an association between RLS and migraine and, in addition, a co-association with depression. The underlying mechanism, however, remains undetermined and might be related to a dysfunction of dopaminergic metabolism in migraine."],["dc.identifier.doi","10.1111/j.1468-2982.2007.01453.x"],["dc.identifier.isi","000250402900009"],["dc.identifier.pmid","17888079"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49836"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0333-1024"],["dc.title","Comorbidity of migraine and restless legs syndrome - a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Canelo, M."],["dc.date.accessioned","2018-11-07T08:48:06Z"],["dc.date.available","2018-11-07T08:48:06Z"],["dc.date.issued","2005"],["dc.format.extent","A266"],["dc.identifier.isi","000228906101298"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21124"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","19th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Denver, CO"],["dc.relation.issn","0161-8105"],["dc.title","Pramipexole reduces the impact of RLS symptoms on daily functioning"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S495"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S504"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Nass, Alexander"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","O'Keeffe, Shaun"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Sieminski, Mariusz"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Wetter, Thomas C."],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Zucconi, Marco"],["dc.date.accessioned","2018-11-07T11:07:07Z"],["dc.date.available","2018-11-07T11:07:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed study designs and evaluation methods in investigator-initiated trials early in the 1990s, and all members have since contributed to many pivotal and nonpivotal drug trials for the treatment of RLS. The recommendations on clinical investigations of pharmacological treatment of RLS patients summarize the group's expertise and knowledge acquired through clinical trials. The recommendations primarily address how to plan and conduct confirmatory, randomized clinical studies in patients with idiopathic RLS. Advice is presented for the diagnosis of RLS and clinical and polysomnographic inclusion and exclusion criteria. Primary and secondary endpoints for an evaluation of efficacy are based on a critical description of validated methods for both short- and long-term trials, also in special populations (children, pregnant women, elderly patients). The recommendations include the assessment of augmentation. Finally, general issues including the evaluation of safety and tolerability, as well as specific neurological and cardiovascular risks and sleep attacks/daytime somnolence, are discussed. The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21538"],["dc.identifier.isi","000251605200015"],["dc.identifier.pmid","17530666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52479"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG)"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1511"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","1515"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Tings, T."],["dc.contributor.author","Helmschmied, Kathrin"],["dc.contributor.author","Neubert, K."],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T10:43:34Z"],["dc.date.available","2018-11-07T10:43:34Z"],["dc.date.issued","2004"],["dc.description.abstract","Challenge with low-dose apomorphine causes a significant rise in growth hormone (GH) in patients with Parkinson's disease (PD) compared to controls and patients with multiple system atrophy (MSA) who have not previously received dopaminergic treatment. To date, it has not been demonstrated whether an apomorphine-induced rise in GH can still be detected in PD patients who are currently treated with levodopa. We investigated whether an ongoing treatment with levodopa influences the GH response to subcutaneously applied low-dose apomorphine in PD patients. We studied 44 patients with idiopathic PD using the low-dose apomorphine test. Twenty-three patients were under treatment with levodopa and 21 patients were without any dopaminergic therapy. GH and cortisol levels were analyzed at time of injection and 45 minutes and 60 minutes after subcutaneous apomorphine injection. Forty-five minutes after apomorphine injection, there was no significant difference between the mean rise in plasma GH in untreated PD patients compared with levodopa-treated patients (P = 0.235). There was no increase of cortisol levels in each treatment group. Age, sex, duration, and severity of the disease did not show a covariate effect with GH levels. A small group of PD patients (n = 8) treated with dopamine agonists and a small group of patients with MSA (n = 5) as well as patients with vascular parkinsonism (n = 5) did not show any increase of GH. Our data suggest that the apomorphine-induced rise in GH does not depend on previous levodopa treatment in PD patients but, as expected, is blocked by dopamine agonists and is not present in patients with other than idiopathic parkinsonian syndrome. Thus, the low-dose apomorphine test may also be a useful biological marker in the early differential diagnosis of PD patients who have already received levodopa treatment. (C) 2004 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.20244"],["dc.identifier.isi","000225774100023"],["dc.identifier.pmid","15390061"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47084"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]